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Dear Editor,
The emergence of endocrine disease has created significant 
challenges for healthcare policy-makers and payers across 
the world. Policy-makers have to ensure availability of drugs 
used for various endocrinopathies. One way in which this is 
facilitated is through the World Health Organization (WHO) 
List of Essential Medicines (LEM). The LEM aims to cover the 
basic pharmaceutical needs of the majority of people seeking 
healthcare (1).
The unique nature of paediatric health is well-known. The 
WHO’s Model LEM for Children, issued in April 2013, covers 
the needs of children up to 12 years of age (2). In its core list, 
it includes drugs for priority conditions, which “are selected 
on the basis of current and estimate future public health 
relevance and potential for safe and cost-effective treatment”. 
The complementary list includes important medicinal drugs 
which do not necessarily fit the above definition, but are 
required in routine clinical practice. 
The list enumerates various “hormones, other endocrine 
drugs and contraceptives”. Levothyroxine is included as 
a core medicine in strengths of 25, 50 and 100 mcg. The 
complementary list includes Lugol’s iodine, potassium iodide, 
and propylthiouracil (2). Adrenal hormones included are oral 
fludrocortisone and hydrocortisone (2). Diabetes is covered by 
soluble insulin, and intermediate-acting insulin (compound 
insulin zinc suspension or isophane insulin). Metformin is 
listed as a complementary medicine, while glucagon 1 mg/ml 
is included in the core list (2). A separate section on ‘vitamins 
and minerals’ lists liquid (400 IU/ml) and solid dosage forms 
(400 IU, 1,000 IU) of cholecalciferol, while mentioning 
ergocalciferol as an alternative (2).
From an endocrine perspective, the inclusion of these drugs 
is laudable. Paediatric thyroid disorders are increasing in 
prevalence, and adrenal disorders, though not as common, are 
life threatening if not treated. The diabetes pandemic has not 
spared children and insulin, a life-saving drug, is mandatory in 
any paediatric LEM.  The mention of glucagon, an emergency 
drug for management of  hypoglycemia, is praise worthy. 
A few omissions, though, need to be highlighted. No pituitary 
drug (growth hormone) is mentioned in the LEM. Similarly 
methimazole or carbimazole, which are safe anti thyroid drugs, 
are not included. The diabetes pharmacotherapeutic landscape 
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is very vast. The current LEM includes human insulins, and 
allows basal-bolus and split-mix regimes be used. These are 
difficult to follow in primary care practice, and premixed 
insulin may be needed in some settings (3). ‘Compound insulin 
zinc’ is no longer manufactured, and should be deleted (4). The 
advantages of insulin analogues (lower risk of hypoglycemia) 
are well-documented (5). Therefore, insulin analogues should 
be added as complementary drugs. Metformin, an economical 
drug, frequently used in paediatrics, (6) deserves a shift to the 
core list. A relook at the omission of calcium is necessary, too.
The WHO Model LEM for Children provides a framework for 
ensuring availability of essential drugs across the world. With 
the increase in prevalence of paediatric endocrine morbidity, 
renewed emphasis on the inclusion of appropriate endocrine 
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